Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $1,381,980.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $230.33, for a total transaction of $1,381,980.00. Following the completion of the sale, the director directly owned 345,875 shares in the company, valued at approximately $79,665,388.75. This trade represents a 1.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ opened at $231.19 on Thursday. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. The company has a 50-day moving average price of $245.68 and a 200-day moving average price of $230.80. The company has a market cap of $15.01 billion, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 0.21 and a beta of 0.37. Jazz Pharmaceuticals PLC has a 12 month low of $128.80 and a 12 month high of $266.38.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.11 billion. During the same period in the previous year, the business earned ($8.25) earnings per share. The firm’s revenue for the quarter was up 15.5% compared to the same quarter last year. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.61 EPS for the current year.

Wall Street Analyst Weigh In

JAZZ has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the company a “buy” rating in a research report on Wednesday, August 26th. Barclays lifted their target price on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an “overweight” rating in a research note on Thursday, September 10th. Royal Bank Of Canada set a $299.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, August 28th. JPMorgan Chase & Co. increased their price target on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Finally, Bank of America raised their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a “buy” rating in a report on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Buy” and an average target price of $291.40.

Institutional Trading of Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in JAZZ. Allianz Asset Management GmbH increased its holdings in shares of Jazz Pharmaceuticals by 68.2% during the fourth quarter. Allianz Asset Management GmbH now owns 598,832 shares of the specialty pharmaceutical company’s stock valued at $101,801,000 after acquiring an additional 242,892 shares in the last quarter. Castleark Management LLC bought a new position in Jazz Pharmaceuticals in the 1st quarter worth about $9,214,000. SEB Asset Management AB bought a new position in Jazz Pharmaceuticals in the 1st quarter worth about $8,765,000. Bank of America Corp DE grew its position in Jazz Pharmaceuticals by 10.9% during the 1st quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after purchasing an additional 99,656 shares during the last quarter. Finally, California Public Employees Retirement System grew its position in Jazz Pharmaceuticals by 10.6% during the 1st quarter. California Public Employees Retirement System now owns 124,583 shares of the specialty pharmaceutical company’s stock valued at $23,552,000 after purchasing an additional 11,915 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious neurological and oncology-related conditions. Founded in 2003 and headquartered in Dublin, Ireland, the company operates internationally, with a significant commercial presence in the United States and other markets.

Jazz’s neuroscience portfolio includes Xywav and Xyrem, which contain oxybate and are used to treat narcolepsy-related symptoms; Xywav is also approved for idiopathic hypersomnia in adults.